Skip to main content

Xtant Medical Holdings, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

XTNT$0.28-3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Operations

(In thousands, except number of shares and per share amounts)

Year Ended December 31,
20252024
Revenue
Product revenue$115,204$115,765
License revenue18,7231,502
Total Revenue133,927117,267
Cost of Sales49,65449,051
Gross Profit84,27368,216
Operating Expenses
General and administrative29,37528,691
Sales and marketing45,51249,214
Research and development2,1022,385
Total Operating Expenses76,98980,290
Income (Loss) from Operations7,284(12,074)
Other (Expense) Income
Interest expense(3,671)(4,160)
Interest income94—
Unrealized foreign currency translation (loss) gain(60)5
Gain on divestiture3,281—
Other income (expense)73(33)
Total Other (Expense) Income(283)(4,188)
Net Income (Loss) from Operations Before Provision for Income Taxes7,001(16,262)
Provision for Income Taxes Current and Deferred(2,028)(187)
Net Income (Loss)$4,973$(16,449)
Net Income (Loss) Per Share:
Basic$0.04$(0.12)
Dilutive$0.03$(0.12)
Shares used in the computation:
Basic139,531,791133,665,075
Dilutive150,042,556133,665,075
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.